Brenntag SE (BNTGF.PK), Wednesday announced an exclusive distribution agreement with ArcticZymes AS on the salt-active nucleases - SAN HQ, SAN-HQ GMP, M-SAN HQ, M-SAN HQ GMP.
With Brenntag's well-established distribution channels and broad market access, ArcticZymes pioneering endonucleases expects to meet a wider range of customers.
Joakim Rehné, Regional President Brenntag Pharma EMEA, commented, "By expanding our portfolio with high-quality enzymes, we support our customers from the early research phase through to full commercialization."
On Monday, Brenntag's stock closed at $53.99 on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.